# Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

Study · id `cardio:ct-nct01560624` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01560624](<https://clinicaltrials.gov/study/NCT01560624>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01560624

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 690 participants.

## Technical summary

Registry record NCT01560624. Randomized; quadruple masking; primary purpose treatment. Start 2012-06-26 (actual); primary completion 2018-06-24 (actual). Results posted on 2020-02-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 690 participants (enrolled count; ClinicalTrials.gov record NCT01560624, source copy `cardio:ctgov-nct01560624-2020-02-13`, retrieved 2026-10-31)
- Started: 2012-06-26 (actual) (ClinicalTrials.gov record NCT01560624, source copy `cardio:ctgov-nct01560624-2020-02-13`, retrieved 2026-10-31)
- Primary completion: 2018-06-24 (actual) (ClinicalTrials.gov record NCT01560624, source copy `cardio:ctgov-nct01560624-2020-02-13`, retrieved 2026-10-31)
- Completion: 2018-06-24 (actual) (ClinicalTrials.gov record NCT01560624, source copy `cardio:ctgov-nct01560624-2020-02-13`, retrieved 2026-10-31)
- Results first posted: 2020-02-13 (ClinicalTrials.gov record NCT01560624, source copy `cardio:ctgov-nct01560624-2020-02-13`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Brazil; Canada; Chile; China; Denmark; France; Germany; Greece; India; Israel; Italy; Mexico; Netherlands; Poland; Singapore; South Korea; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT01560624, source copy `cardio:ctgov-nct01560624-2020-02-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01560624-2020-02-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
- Acronym: FREEDOM-EV
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Treprostinil Diolamine
- Intervention (Drug): Placebo
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

## Provenance

Content hash: b63256ed1d7e3ec9663d987d3a9943028604a4e6dd423509ac2717014bee6755
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
